Literature DB >> 23676457

Transplant rejection and paradigms lost.

Terry B Strom1.   

Abstract

During transplant rejection, migrating T cells infiltrate the grafted organ, but the signals that direct this migration are incompletely understood. In this issue of the JCI, Walch et al. debunk two classical paradigms concerning transplant rejection, with important consequences for the design of antirejection therapeutics.

Mesh：

Year:  2013        PMID： 23676457      PMCID： PMC3668827          DOI： 10.1172/JCI69385

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  13 in total

Review 1.  Chemokines and their receptors in allograft rejection.

Authors:  W W Hancock; W Gao; K L Faia; V Csizmadia
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

2.  The puzzling role of CXCR3 and its ligands in organ allograft rejection.

Authors:  P F Halloran; R L Fairchild
Journal:  Am J Transplant       Date:  2008-08       Impact factor: 8.086

Review 3.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

4.  Cognate antigen directs CD8+ T cell migration to vascularized transplants.

Authors:  Jeffrey M Walch; Qiang Zeng; Qi Li; Martin H Oberbarnscheidt; Rosemary A Hoffman; Amanda L Williams; David M Rothstein; Warren D Shlomchik; Jiyun V Kim; Geoffrey Camirand; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

5.  Cellular and molecular events in the localization of diabetogenic T cells to islets of Langerhans.

Authors:  Boris Calderon; Javier A Carrero; Mark J Miller; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

6.  Entry of diabetogenic T cells into islets induces changes that lead to amplification of the cellular response.

Authors:  Boris Calderon; Javier A Carrero; Mark J Miller; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

7.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

8.  The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.

Authors:  S Bolt; E Routledge; I Lloyd; L Chatenoud; H Pope; S D Gorman; M Clark; H Waldmann
Journal:  Eur J Immunol       Date:  1993-02       Impact factor: 5.532

9.  Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin.

Authors:  Ziv Shulman; Vera Shinder; Eugenia Klein; Valentin Grabovsky; Orna Yeger; Erez Geron; Alessio Montresor; Matteo Bolomini-Vittori; Sara W Feigelson; Tomas Kirchhausen; Carlo Laudanna; Guy Shakhar; Ronen Alon
Journal:  Immunity       Date:  2009-03-05       Impact factor: 31.745

Review 10.  CD3-specific antibodies: a portal to the treatment of autoimmunity.

Authors:  Lucienne Chatenoud; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2007-07-20       Impact factor: 53.106
View more
  1 in total

1.  Inhibition of Autophagy Prolongs Recipient Survival Through Promoting CD8+ T Cell Apoptosis in a Rat Liver Transplantation Model.

Authors:  Xiaolong Chen; Li Wang; Yinan Deng; Xuejiao Li; Guolin Li; Jing Zhou; Daorou Cheng; Yang Yang; Qing Yang; Guihua Chen; Genshu Wang
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.